Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasisFootnote

Peer review under responsibility of Alexandria University Faculty of Medicine.

Footnote

Available online 7 February 2014

References

• D.M.ParkinF.BrayJ.FerlayP.PisaniGlobal cancer statistics, 2002CA Cancer J Clin55200574108
   PubMed Web of Science ®Google Scholar
• Al-Eid HS, Arteh SO. Saudi cancer registry reports. Cancer incidence report Saudi Arabia 2005. 2009;18–19. <http://www.scr.org.sa>; [accessed 26 May 2012].
   Google Scholar
• C.R.BolandF.A.SinicropeD.E.BrennerJ.M.CarethersColorectal cancer prevention and treatmentGastroenterology182 Suppl. 12000S115S128
   Google Scholar
• G.SmithF.A.CareyJ.BeattieM.J.WilkieT.J.LightfootJ.CoxheadMutations in APC, Kirsten-ras, and p53 – alternative genetic pathways to colorectal cancerProc Natl Acad Sci USA99200294339438
   PubMed Web of Science ®Google Scholar
• D.CalistriC.RengucciI.SeymourA.LattunedduA.M.PolifemoF.MontiMutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progressionJ Cell Physiol20422005484488
   Web of Science ®Google Scholar
• Y.X.RenG.M.XuZ.S.LiY.G.SongDetection of pointmutation in K-ras oncogene at codon 12 in pancreatic diseasesWorld J Gastroenterol102004881884
   PubMed Web of Science ®Google Scholar
• J.W.ArendsMolecular interactions in the Vogelstein model of colorectalcarcinomaJ Pathol1902000412416
   PubMed Web of Science ®Google Scholar
• T.TakayamaK.MiyanishiT.HayashiY.SatoY.NiitsuColorectal cancer: genetics of development and metastasisJ Gastroenterol4132006185192
   PubMed Web of Science ®Google Scholar
• D.L.WorthleyV.L.WhitehallK.J.SpringB.A.LeggettColorectal carcinogenesis: road maps to cancerWorld J Gastroenterol1328200737843791
   Web of Science ®Google Scholar
• E.KerkhoffU.R.RappCell cycle targets of Ras/Raf signallingOncogene17199814571462
   PubMed Web of Science ®Google Scholar
• A.LeslieF.A.CareyN.R.PrattR.J.SteeleThe colorectal adenomacarcinoma sequenceBr J Surg2002892002845860
   Google Scholar
• H.ChongH.G.VikisK.L.GuanMechanisms of regulating the Raf kinase familyCell Signal2003152003463469
   Google Scholar
• S.BenvenutiA.Sartore-BianchiF.Di NicolantonioC.ZanonM.MoroniS.VeroneseOncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapiesCancer Res676200726432648
   PubMed Web of Science ®Google Scholar
• F.Di FioreF.BlanchardF.CharbonnierF.Le PessotA.LamyM.P.GalaisClinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBr J Cancer968200711661169
   PubMed Web of Science ®Google Scholar
• S.Khambata-FordC.R.GarrettN.J.MeropolM.BasikC.T.HarbisonS.WuExpression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximabJ Clin Oncol2522200732303237
   PubMed Web of Science ®Google Scholar
• R.G.AmadoM.WolfM.PeetersE.Van CutsemS.SienaD.J.FreemanWild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancerJ Clin Oncol26200816261634
   PubMed Web of Science ®Google Scholar
• W.De RoockH.PiessevauxJ.De SchutterM.JanssensG.De HertoghN.PersoneniKRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximabAnn Oncol1932008508515
   PubMed Web of Science ®Google Scholar
• A.LièvreJ.B.BachetV.BoigeA.CayreD.Le CorreE.BucKRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximabJ Clin Oncol2632008374379
   PubMed Web of Science ®Google Scholar
• E.Van CutsemM.PeetersS.SienaY.HumbletA.HendliszB.NeynsOpen-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancerJ Clin Oncol2513200716581664
   PubMed Web of Science ®Google Scholar
• C.BokemeyerI.BondarenkoA.MakhsonJ.T.HartmannJ.AparicioF.de BraudFluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancerJ Clin Oncol2752009663671
   PubMed Web of Science ®Google Scholar
• C.J.AllegraJ.M.JessupM.R.SomerfieldS.R.HamiltonE.H.HammondD.F.HayesAmerican Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapyJ Clin Oncol2712200920912096
   PubMed Web of Science ®Google Scholar
• P.EstradaA.Rojas-AtencioW.ZabalaL.BorjasL.SocaK.UrdanetaFrequency and clinicopathological associations of K-ras mutations in Venezuelan patients with colo-rectal cancerInvest Clin50120095563
   Web of Science ®Google Scholar
• M.BrinkA.F.de GoeijM.P.WeijenbergG.M.RoemenM.H.LentjesM.M.PachenK-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort StudyCarcinogenesis2442003703710
   PubMed Web of Science ®Google Scholar
• P.MinooI.ZlobecM.PetersonL.TerraccianoA.LugliCharacterization of rectal, proximal and distal colon cancers based on clinicopathological, molecular and protein profilesInt J Oncol3732010707718
   Web of Science ®Google Scholar
• A.S.SameerN.A.ChowdhriS.AbdullahZ.A.ShahM.A.SiddiqiMutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a reportIndian J Cancer4632009219225
   Google Scholar
• W.WeichertC.ScheweA.LehmannC.SersKRAS genotyping of paraffin-embedded colorectal cancer tissue in routine diagnostics: comparison of methods and impact of histologyJ Mol Diagn12120103542
   PubMed Web of Science ®Google Scholar
• P.TherasseS.G.ArbuckE.A.EisenhauerJ.WandersR.S.KaplanL.RubinsteinNew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst9232000205216
   PubMed Web of Science ®Google Scholar
• A.M.AljebreenClinico-pathologicalpatterns of colorectalcancer in Saudi Arabia: younger with an advanced stage presentationSaudi J Gastroenterol13220078487
   PubMedGoogle Scholar
• W.H.IsbisterColorectal cancer below age 40 in the Kingdom of Saudi ArabiaAust N Z J Surg6261992468472
   PubMedGoogle Scholar
• J.J.OudejansR.J.SlebosF.A.ZoetmulderW.J.MooiS.RodenhuisDifferential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liverInt J Cancer4961991875879
   PubMed Web of Science ®Google Scholar
• P.CejasM.López-GómezC.AguayoR.MaderoJ.de Castro CarpeñoKRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasisPLoS One4122009 e8199, 1–6.
   Web of Science ®Google Scholar
• M.YamauchiP.LochheadI.MorkiawaA.T.Huttenhower CChenColorectal cancer a tale of two sides or a continuum?Gut6162012794797
   PubMed Web of Science ®Google Scholar
• JeanneTieLaraLiptonJayeshDesaiPeterGibbsRobert N.JorissenKRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancerClin Cancer Res175201111221130
   PubMed Web of Science ®Google Scholar
• Mi-JungKimHye SeungLeeJeeHyunDifferent metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancerBMC Cancer122012347
   PubMed Web of Science ®Google Scholar